FDA Approved: RIFADIN IV — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for Rifadin IV (rifampin) by Sanofi-Aventis U.S. LLC to support its intravenous formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Tuberculosis

Drugs mentioned

• RIFADIN IV (rifampin)

Snippet

SUPPL AP for RIFADIN IV (RIFAMPIN)